Mycofenolate Mofetil Aurobindo (Mycophenolate Mofetil)

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH). By blocking this enzyme, the drug reduces guanosine nucleotide synthesis, a critical step for the proliferation of T‑ and B‑lymphocytes, thereby dampening the immune response.

The dosage of Mycofenolate Mofetil Aurobindo is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Safety data for mycophenolate mofetil in pregnancy are limited, and the drug is generally contraindicated because of potential teratogenic effects. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended while on therapy, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mycophenolate mofetil differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcium‑dependent signaling. This results in a distinct side‑effect profile, with less nephrotoxicity but a higher incidence of gastrointestinal upset and bone‑marrow suppression. Choice of therapy depends on the transplant protocol and patient tolerance.

Store Mycofenolate Mofetil Aurobindo at temperatures below 25 °C, in its original container, protected from moisture, heat and direct light. Do not refrigerate or freeze the product unless the label specifically indicates otherwise.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact timing (e.g., twice daily) and whether it should be taken with or without meals are determined by the prescribing clinician based on the therapeutic regimen.

Serious risks include severe bone‑marrow suppression leading to leukopenia or anemia, opportunistic infections, hepatic toxicity, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly with blood tests and clinical assessments to detect these complications early.

Mycofenolate Mofetil Aurobindo is contraindicated in patients with known hypersensitivity to mycophenolate or any component of the formulation, in those with active uncontrolled infections, and in pregnant women unless the benefits clearly outweigh the risks. Caution is also advised for individuals with severe renal impairment.